Halozyme Therapeutics Inc (HALO) Stock Analysis
Verdict: BUY
High-margin royalty growth from the ENHANZE platform justifies a premium, but heavy insider selling and 52-week highs limit near-term upside.
Investment score: 68/100
Analysis as of
Is Halozyme Therapeutics Inc stock worth reviewing? AI model thesis
Halozyme is exhibiting exceptional operational momentum with 41% revenue growth and massive margins. However, the stock has run 25% in five days and is trading at the very top of its analyst target range ($99-$115). Holding is prudent to capture further royalty expansion while avoiding entry at a local peak.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Halozyme Therapeutics Inc opportunities and risks
What speaks for HALO
- ENHANZE Platform Scalability
What speaks against HALO
- Aggressive Insider Selling
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HALO | 29.3x | 7.4x | 20.9x | 78.2% | 24.9% | 6.6% |
| BBIO | n/a | 28.5x | n/a | 93.8% | -125.2% | -2.7% |
| EXEL | 16.4x | 5.6x | 13.0x | 96.5% | 35.3% | 10.5% |
| ARWR | n/a | 18.4x | n/a | 100.0% | -47.8% | -0.6% |
| BMRN | 167.9x | 3.6x | 40.6x | 75.5% | 2.1% | 7.6% |
| MDGL | n/a | 9.2x | n/a | 91.5% | -25.3% | -1.8% |
| Peer median | n/a | 9.2x | n/a | 93.8% | -25.3% | -0.6% |
Frequently asked questions about Halozyme Therapeutics Inc (HALO)
Is HALO stock a good investment?
The cached TradeMates AI model rates Halozyme Therapeutics Inc as BUY with an investment score of 68/100. Halozyme is exhibiting exceptional operational momentum with 41% revenue growth and massive margins. However, the stock has run 25% in five days and is trading at the very top of its analyst target range ($99-$115). Holding is prudent to capture further royalty expansion while avoiding entry at a local peak. This is algorithmic model output, not personal investment advice.
Is HALO stock a buy?
The TradeMates model verdict for HALO is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.